Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.
Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA. Carneiro BA, et al. Among authors: shah an. Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20. Clin Cancer Res. 2018. PMID: 29559559 Free PMC article.
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ. Santa-Maria CA, et al. Among authors: shah an. Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721177 Free PMC article.
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ. Jain S, et al. Among authors: shah an. Breast Cancer Res Treat. 2018 Sep;171(2):371-381. doi: 10.1007/s10549-018-4792-0. Epub 2018 May 30. Breast Cancer Res Treat. 2018. PMID: 29850984 Clinical Trial.
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Gerratana L, Davis AA, Shah AN, Lin C, Corvaja C, Cristofanilli M. Gerratana L, et al. Among authors: shah an. Curr Treat Options Oncol. 2019 Jun 29;20(8):68. doi: 10.1007/s11864-019-0667-9. Curr Treat Options Oncol. 2019. PMID: 31256282 Review.
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA, Zhang Q, Gerratana L, Shah AN, Zhan Y, Qiang W, Finkelman BS, Flaum L, Behdad A, Gradishar WJ, Platanias LC, Cristofanilli M. Davis AA, et al. Among authors: shah an. Breast Cancer Res. 2019 Dec 4;21(1):137. doi: 10.1186/s13058-019-1229-6. Breast Cancer Res. 2019. PMID: 31801599 Free PMC article.
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
Gerratana L, Zhang Q, Shah AN, Davis AA, Zhang Y, Wehbe F, Qiang W, Flaum L, Finkelman BS, Gradishar WJ, Platanias LC, Behdad A, Cristofanilli M. Gerratana L, et al. Among authors: shah an. Crit Rev Oncol Hematol. 2020 Jan;145:102856. doi: 10.1016/j.critrevonc.2019.102856. Epub 2019 Dec 23. Crit Rev Oncol Hematol. 2020. PMID: 31884205 Review.
339 results